The BPTH chart settings shown below allow you to select time intervals of 1 min, 30 mins, an hour or by day - week - month. There is also the ability to change the BPTH chart style to candles, hollow candles, bars, lines or add various indicators. You can even add a symbol and compare history.
The BPTH stock resources shown below were gathered to cut back on time by allowing you to visit multiple sites at once. For your convenience each link clicked will open in a window. In addition to the individual links there is a button at the bottom that will allow you to open all the links at the same time. Note opening all links at once may not work with all browsers. Some browsers block multiple windows, to resolve this please allow that site to use pop-ups.
|View BPTH Detailed Price Forecast - CNN Money||View BPTH Detailed Summary - Google Finance|
|View BPTH Detailed Summary - Yahoo! Finance||View BPTH Stock Research & Analysis - Zacks.com|
|View BPTH Trends & Analysis - Trade-Ideas||View BPTH Major Holders - Barrons|
|View BPTH Call Transcripts - NASDAQ||View BPTH Breaking News & Analysis - Seeking Alpha|
|View BPTH Annual Report - CompanySpotlight.com||View BPTH OTC Short Report - OTCShortReport.com|
|View BPTH Fundamentals - TradeKing||View BPTH SEC Filings - Bar Chart|
|View Historical Prices for BPTH - The WSJ||View Performance/Total Return for BPTH - Morningstar|
|View the Analyst Estimates for BPTH - MarketWatch||View the Earnings History for BPTH - CNBC|
|View the BPTH Earnings - StockMarketWatch||View BPTH Buy or Sell Recommendations - MacroAxis|
|View the BPTH Bullish Patterns - American Bulls||View BPTH Short Pain Metrics - ShortPainBot.com|
|View BPTH Stock Mentions - StockTwits||View BPTH Stock Mentions - PennyStockTweets|
|View BPTH Stock Mentions - Twitter||View BPTH Investment Forum News - Investor Hub|
|View BPTH Stock Mentions - Yahoo! Message Board||View BPTH Stock Mentions - Seeking Alpha|
|View Insider Transactions for BPTH - SECform4.com||View Insider Transactions for BPTH - Insider Cow|
|View BPTH Major Holdings Summary - CNBC||View Insider Disclosure for BPTH - OTC Markets|
|View Insider Transactions for BPTH - Yahoo! Finance||View Institutional Holdings for BPTH - NASDAQ|
|View BPTH Stock Insight & Charts - FinViz.com||View BPTH Investment Charts - StockCharts.com|
|View BPTH Stock Overview & Charts - BarChart||View BPTH User Generated Charts - Trading View|
Pre-Clinical Data Demonstrating Promising Potential of Prexigebersen as Treatment for Solid Tumors in Gynecologic Malignancies Presented at American Association for Cancer Research Annual Meeting
Posted on Wednesday April 18, 2018
Bio-Path Holdings, Inc., (BPTH), a biotechnology company leveraging its proprietary DNAbilize® antisense RNAi nanoparticle technology to develop a portfolio of targeted nucleic acid cancer drugs, today announced that data from pre-clinical studies supporting the potential of prexigebersen (BP1001, liposomal Grb2 antisense), in the treatment of solid tumors in gynecologic malignancies were presented in a poster at the annual meeting of the American Association for Cancer Research (AACR), which took place in Chicago, IL. The poster titled, “Grabbing GRB2: The use of Liposome-incorporated Grb2 antisense oligonucleotides as a novel therapy in gynecologic malignancies,” was presented by Olivia D. Lara, M.D., University of Texas MD Anderson Cancer Center, Department of Gynecologic Oncology during the Experimental and Molecular Therapeutics Poster Session. The data summarize results from studies investigating the expression of GRB2 in a series of in vitro experiments in high-grade serous (HGSC) and uterine (UC) carcinoma models. The study also examined the biological effects of prexigebersen in HGSC mice models (OVCAR 5), first in a dose-defining experiment then in combination with standard dose paclitaxel.
Wired News – EMA Completed Validation of MAA for Aradigm’s Linhaliq in Non-Cystic Fibrosis Bronchiectasis
Posted on Monday April 09, 2018
Stock Monitor: Bio-Path Holdings Post Earnings Reporting LONDON, UK / ACCESSWIRE / April 09, 2018 / Active-Investors.com has just released a free research report on Aradigm Corp. (NASDAQ: ARDM ). If you ...
Bio-Path Leukemia Combo Study Shows Positive Early Data
Posted on Wednesday April 04, 2018
Bio-Path (BPTH) announces positive interim data from phase II study of its lead pipeline candidate ??? prexigebersen ??? in combination with low-dose cytarabine (LDAC) for leukemia patients.
Bio-Path: Why the Biotech Penny Stock Is Skyrocketing Today
Posted on Tuesday April 03, 2018
The other bit of good news for BPTH stock today was financial results for its fiscal full year of 2017. During the year, the company reported a net loss of $8.1 million, or 80 cents per share. This is a wider net loss than the $6.8 million, or 73 cents per share from the year prior.